Chimeric antigen receptor (CAR) T-cells have changed treatment avenues in #hematology, providing new hope for patients.
Its road started quite recently, with highs and lows; and it remains a very complex and expensive treatment.
A short 🧵about its history.
#MedTwitter
As you read the #ASCO22 abstracts, here are some tips I offer to separate true & useful from all the rest
PS: The Amgen ad on the banner of the abstract page is emblematic of what you have to contend with
🧵
Dear Sir @narendramodi@PMOIndia@mansukhmandviya@MoHFW_INDIA
Every year about 77, 000 children with cancer are diagnosed in India. Which is 20% Global burden. Only 26,000 (34%) reach a cancer centre. Kindly requesting you to include pediatric cancer in national cancer policy.
How I Treat Myeloma: 2022 Update.
10 slides. Hope it's useful for oncologists and patients. @NorthTxMSG@MyelomaTeacher
1/ Risk stratification: This is important both for counseling patients and to decide on treatment options. The more high risk factors, the higher the risk.
Starting a new job as a Consultant Hemato Oncologist and BMT physician at Yashoda Hospitals, Somajiguda, Hyderabad @ Yashoda Hospital, Somajiguda https://t.co/xhW6EwV57w
My appeal to #IAS Officers leading #COVID19 response in #States & #Districts: Please don't hold daily reviews with #Doctors responsible for public health & hospital management services. Their work is with people, in health centres & Hospitals, not before video cameras. #PleaseRT
Another first for Manipal Hospitals, Vijayawada & Andhra Pradesh. First successful Haplo match Allogeneic Stem Cell Transplant using TBI, with complete AP Govt financial assistance. We would like to thank our CM @ysjagan sir and @HariKrishnaCMO for making this possible.
Click on the link to find out more about What a Bone Marrow Transplant is ? https://t.co/qpOZBta89I via @YouTube
Don’t forget to subscribe to the channel😄
Excited to share our work published in JCO Global Oncology!
Walking a Tightrope: Dosage Modifications and Treatment Outcomes of ATRA, ATO, and DNR for High-Risk Acute Promyelocytic Leukemia
https://t.co/9Jkl6c85B1 @ASCO@ASCO_pubs@ManipalHealth